The Newsroom

Investigations  /  07.16.2020

Investigation of Chembio Diagnostics, Inc.

You Have Legal Options

Chembio Diagnostics, Inc. (CEMI) Accused of Misleading Shareholders 

In March 2020, Chembio entered into a strategic partnership to begin the development of a diagnostic test for the detection of the COVID-19 virus and IgM and IgG antibodies. Throughout the relevant period, Chembio touted that its antibody test provides high sensitivity and specificity, and was 100% accurate. As a result of these positive representations, Chembio’s stock price soared from a closing price of $5.12 per share on March 31, 2020 to a closing price of $15.54 per share on April 24, 2020. Chembio took advantage of the stock’s trading success and closed the public offering of 2.6 million shares at $11.75 per share for gross proceeds of approximately $30.8 million on May 11, 2020.  Despite Chembio’s purported success, on June 17, 2020, the Company disclosed that the FDA had revoked its Emergency Use Authorization of Chembio’s antibody test “due to performance concerns with the accuracy of the test.” On this news, Chembio’s shares fell $6.04, or 60%, to close at $3.89 per share.

If you purchased Chembio Diagnostics, Inc. (CEMI) securities between March 12, 2020 and June 16, 2020, you have until August 17, 2020, to ask the court to be appointed lead plaintiff for the class.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns